

Technology Appraisal Committee Meeting (Committee B)

Minutes: **Confirmed**

Date and Time: Thursday 4 August 2016 10am to 5pm

Venue: Royal College of General Practitioners, 30 Euston Square, London NW1 2FB

Present:	1. Dr Amanda Adler (Chair) 2. Dr Sanjeev Patel (Vice-Chair) 3. Dr Jeff Aronson 4. Professor John Cairns 5. Mr Mark Chapman 6. Dr Mark Glover 7. Dr Sumeet Gupta 8. Mrs Anne Joshua 9. Dr Sanjay Kinra 10. Dr Miriam McCarthy 11. Professor Ruairidh Milne 12. Mr Christopher O'Regan 13. Professor John Pounsford 14. Dr Danielle Preedy 15. Dr Nicky Welton 16. Mr Nigel Westwood	Present for all notes Present for all notes
-----------------	--	---

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Administrator, National Institute for Health and Care Excellence	Present for all notes
Raisa Sidhu	Technical Adviser,	Present for notes 1 to 14

	National Institute for Health and Clinical Excellence	
Jasdeep Hayre	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 15 to 27
Rachid Rafia	Research Fellow, School of Health and Related Research	Present for notes 15 to 24

Non-public observers:

Helen Barnett	Medical Editor, NICE	Present for all notes
Robert Kettell	Deputy Director – Pricing, Prescriptions and Supply Medicines and Pharmacy Directorate, Department of Health	Present for all notes
David Meads	New Member of Committee D	Present for all notes
Pilar Pinilla-Dominguez	Technical Adviser, NICE Scientific Advice	Present for notes 1 to 14

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of ibrutinib for treating chronic lymphocytic leukaemia [ID749] and pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837]
2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Robert Kettell, David Meads and Pilar Pinilla-Dominguez.
3. Apologies were received from Dr Ray Armstrong, Dr Neil Iosson, Professor Stephen Palmer, Mr Alun Roebuck, Dr Nigel De-Kare Silver and Professor Ken Stein.

Any other Business

4. The Committee were given an update on other appraisals including an update on TA391 cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel.

Appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749]

Part 1 – Open session

5. The Chair welcomed company representatives from Janssen to the meeting.

6. The Chair asked all Committee members to declare any relevant interests
 - 6.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Sumeet Gupta, Mrs Anne Joshua, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor John Poundsford, Dr Danielle Preedy, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749].
7. The Chair asked all NICE Staff to declare any relevant interests.
 - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749].
8. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
9. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
10. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
11. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

12. The Committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia [ID749].
 - 12.1. The committee decision was based on consensus.
13. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Notes from the last meeting

14. The minutes of the meetings held on 8 June 2016 and 6 July 2016 were approved.

Appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837]

Part 1 – Open session

15. The Chair welcomed the invited experts: Rachid Rafia to the meeting and he introduced himself to the Committee.
16. The Chair welcomed company representatives from Roche to the meeting.
17. The Chair asked all Committee members to declare any relevant interests
 - 17.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Sumeet Gupta, Mrs Anne Joshua, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Professor John Poundsford, Dr Danielle Preedy, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837].
18. The Chair asked all NICE Staff to declare any relevant interests.
 - 18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837].
19. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 19.1. Rachid Rafia declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837].
20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
22. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

23. The Chair then thanked the Evidence Review Group representative and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. Discussion on confidential information continued. This information was supplied by the company.
 - 24.1. The committee decision was based on consensus.
25. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

26. Wednesday 7 September 2016 at Prospero House, 241 Borough High Street, London SE1 1GA.